Vertex pays CRISPR $900M to take control of sickle cell partnership, betting they can beat bluebird -- and renewing analysts' skepticism

When Vertex chairman Jeffrey Leiden and CRISPR Therapeutics CEO Samarth Kulkarni got on the call for the first meeting of the year, the tenor was …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ver­tex pays CRISPR $900M to take con­trol of sick­le cell part­ner­ship, bet­ting they can beat blue­bird -- and re­new­ing an­a­lyst­s' skep­ti­cism